These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 8704686)

  • 41. [Eradication of adult T-cell leukemia cells and maintenance of remission by the graft-versus-leukemia effect after allogeneic bone marrow transplantation].
    Ota K; Hashino S; Shimizu K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Sep; 45(9):1044-7. PubMed ID: 15510833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
    Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
    Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
    Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
    Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
    Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
    Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cyclosporine-induced graft-versus-host disease in a syngeneic bone marrow transplantation].
    Hashimoto S; Kawano E; Hirasawa A; Morio S; Aotuka N; Nakamura H; Oh H; Asai T; Yoshida S; Ishii G
    Rinsho Ketsueki; 1993 Jan; 34(1):34-8. PubMed ID: 8450605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission.
    Michel G; Maraninchi D; Demeocq F; Perrimond H; Blaise D; Gaspard MH; Stoppa AM; Gastaut JA; Lepeu G; Novakovitch G
    Bone Marrow Transplant; 1988 Mar; 3(2):105-11. PubMed ID: 3048474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy with interleukin 2 after ABMT in AML.
    Hamon MD; Prentice HG; Gottlieb DJ; Macdonald ID; Cunningham JM; Smith OP; Gilmore M; Gandhi L; Collis C
    Bone Marrow Transplant; 1993 May; 11(5):399-401. PubMed ID: 8504274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center.
    Powles R; Mehta J; Singhal S; Horton C; Tait D; Milan S; Pollard C; Lumley H; Matthey F; Shirley J
    Bone Marrow Transplant; 1995 Aug; 16(2):241-7. PubMed ID: 7581142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Autologous bone marrow transfusion in the treatment of adults with hematologic neoplasms. Experiences from Bern].
    Brun del Re GP; Tschopp L; Cerny T; Bucher U
    Schweiz Med Wochenschr; 1989 Jun; 119(25):902-10. PubMed ID: 2667130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
    Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
    Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors.
    Mehta J; Powles R; Singhal S; Horton C; Tait D; Milan S; Meller S; Pinkerton CR; Treleaven J
    Bone Marrow Transplant; 1995 Oct; 16(4):499-506. PubMed ID: 8528164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome of autologous rescue after failed engraftment of allogeneic marrow.
    Mehta J; Powles R; Singhal S; Horton C; Treleaven J
    Bone Marrow Transplant; 1996 Feb; 17(2):213-7. PubMed ID: 8640169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of recipient-specific alloreactivity: is GVHD predictable?
    Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
    Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
    Ericson SG; Colby E; Welch L; Ball ED
    Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autologous unpurged bone marrow transplantation for acute non-lymphoblastic leukaemia in first complete remission.
    Carella AM; Gaozza E; Santini G; Martinengo M; Pungolino E; Piatti G; Congiu A; Nati S; Carlier P; Giordano D
    Bone Marrow Transplant; 1988 Nov; 3(6):537-41. PubMed ID: 3063322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.